1. O Efeito da Doença de Coronavírus 2019 nas Doenças Cardiovasculares
- Author
-
Lütfü Aşkın, Okan Tanriverdi, and Husna Sengul Askin
- Subjects
lcsh:Diseases of the circulatory (Cardiovascular) system ,Comorbidade ,Review Article ,Comorbidity ,030204 cardiovascular system & hematology ,medicine.disease_cause ,0302 clinical medicine ,Pandemic ,Doenças Cardiovasculares/complicações ,Síndrome Respiratória Aguda ,Coronavirus ,Pandemias ,Viral Epidemiology ,Chloroquine ,Hospitalization ,Myocarditis ,Cardiovascular Diseases ,Antirheumatic Agents ,Angiotensin-converting enzyme 2 ,Hypertension ,Mortalidade ,Angiotensin-Converting Enzyme 2 ,Cardiology and Cardiovascular Medicine ,Coronavirus Infections ,COVID 19 ,medicine.medical_specialty ,Cardiovascular Diseases/complications ,China ,Critical Care ,Insuficiência Cardíaca ,Pneumonia, Viral ,Miocardite ,Peptidyl-Dipeptidase A ,Antiviral Agents ,03 medical and health sciences ,Angiotensin Receptor Antagonists ,Betacoronavirus ,Cuidados Críticos ,Internal medicine ,medicine ,Animals ,Humans ,Mortality ,Pandemics ,Artigo de Revisão ,Hospitalização ,Heart Failure ,Acute Respiratory Syndrome ,business.industry ,SARS-CoV-2 ,COVID-19 ,medicine.disease ,Pneumonia ,lcsh:RC666-701 ,Heart failure ,business ,Hipertensão - Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19.A doença de coronavírus 2019 (COVID-19) é uma pandemia global afetando o mundo, estando presente em mais de 1.300.000 pacientes. O COVID-19 age pelo receptor da enzima conversora de angiotensina 2 (ECA2). As comorbidades cardiovasculares são mais frequentes com COVID-19, e cerca 10% de casos desenvolvem miocardite (22% de pacientes críticas). Mais pesquisas serão necessárias para continuar ou descontinuar inibidores de ECA e bloqueadores dos receptores da angiotensina, que são essenciais para hipertensão e insuficiência cardíaca em COVID-19. Pesquisa intensiva é promissora para o tratamento e a prevenção da COVID-19.
- Published
- 2020